Ashfield Capital Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $4.35M | Hold |
99,496
| – | – | 0.37% | 66 |
|
|
2022
Q2 | $5.22M | Buy |
99,496
+800
| +0.8% | +$40.8K | 0.41% | 60 |
|
|
2022
Q1 | $5.11M | Sell |
98,696
-1,034
| -1% | -$53.6K | 0.33% | 69 |
|
|
2021
Q4 | $5.89M | Sell |
99,730
-3,117
| -3% | -$154K | 0.38% | 64 |
|
|
2021
Q3 | $4.42M | Buy |
102,847
+192
| +0.2% | +$8.51K | 0.32% | 71 |
|
|
2021
Q2 | $4.02M | Buy |
102,655
+392
| +0.4% | +$15.2K | 0.29% | 76 |
|
|
2021
Q1 | $3.71M | Buy |
102,263
+242
| +0.2% | +$8.59K | 0.29% | 75 |
|
|
2020
Q4 | $3.75M | Sell |
102,021
-4,666
| -4% | -$171K | 0.3% | 72 |
|
|
2020
Q3 | $3.71M | Sell |
106,687
-484
| -0.5% | -$17K | 0.34% | 68 |
|
|
2020
Q2 | $3.33M | Buy |
107,171
+9,708
| +10% | +$330K | 0.33% | 70 |
|
|
2020
Q1 | $3.02M | Buy |
97,463
+501
| +0.5% | +$17.1K | 0.37% | 64 |
|
|
2019
Q4 | $3.6M | Sell |
96,962
-7,629
| -7% | -$272K | 0.36% | 72 |
|
|
2019
Q3 | $3.56M | Hold |
104,591
| – | – | 0.39% | 72 |
|
|
2019
Q2 | $4.3M | Sell |
104,591
-756
| -0.7% | -$30K | 0.46% | 66 |
|
|
2019
Q1 | $4.25M | Sell |
105,347
-6
| -0% | -$240 | 0.47% | 63 |
|
|
2018
Q4 | $4.36M | Buy |
105,353
+7,513
| +8% | +$312K | 0.57% | 48 |
|
|
2018
Q3 | $4.09M | Sell |
97,840
-579
| -0.6% | -$22.3K | 0.46% | 65 |
|
|
2018
Q2 | $3.39M | Buy |
98,419
+545
| +0.6% | +$18.6K | 0.42% | 68 |
|
|
2018
Q1 | $3.3M | Buy |
97,874
+588
| +0.6% | +$20.2K | 0.43% | 71 |
|
|
2017
Q4 | $3.34M | Sell |
97,286
-2,254
| -2% | -$76.9K | 0.43% | 71 |
|
|
2017
Q3 | $3.37M | Buy |
99,540
+1,502
| +2% | +$48.3K | 0.45% | 66 |
|
|
2017
Q2 | $3.12M | Buy |
98,038
+417
| +0.4% | +$13.2K | 0.43% | 70 |
|
|
2017
Q1 | $3.17M | Buy |
97,621
+26
| +0% | +$820 | 0.44% | 72 |
|
|
2016
Q4 | $3.01M | Buy |
97,595
+906
| +0.9% | +$27.7K | 0.29% | 82 |
|
|
2016
Q3 | $3.11M | Buy |
96,689
+738
| +0.8% | +$24.7K | 0.26% | 84 |
|
|
2016
Q2 | $3.21M | Buy |
95,951
+664
| +0.7% | +$21.2K | 0.26% | 79 |
|
|
2016
Q1 | $2.68M | Sell |
95,287
-3,826
| -4% | -$109K | 0.19% | 96 |
|
|
2015
Q4 | $3.04M | Buy |
99,113
+2,158
| +2% | +$67.9K | 0.21% | 91 |
|
|
2015
Q3 | $2.89M | Sell |
96,955
-1,661
| -2% | -$53.3K | 0.19% | 93 |
|
|
2015
Q2 | $3.14M | Buy |
98,616
+453
| +0.5% | +$14.8K | 0.17% | 95 |
|
|
2015
Q1 | $3.24M | Buy |
98,163
+1,581
| +2% | +$50.3K | 0.17% | 91 |
|
|
2014
Q4 | $2.85M | Sell |
96,582
-639
| -0.7% | -$18.3K | 0.14% | 96 |
|
|
2014
Q3 | $2.73M | Sell |
97,221
-369
| -0.4% | -$10.4K | 0.13% | 99 |
|
|
2014
Q2 | $2.75M | Sell |
97,590
-5,172
| -5% | -$147K | 0.13% | 101 |
|
|
2014
Q1 | $3.13M | Buy |
102,762
+2,884
| +3% | +$86K | 0.15% | 95 |
|
|
2013
Q4 | $2.9M | Buy |
99,878
+1,018
| +1% | +$29.6K | 0.14% | 95 |
|
|
2013
Q3 | $2.69M | Buy |
98,860
+2,205
| +2% | +$60K | 0.14% | 96 |
|
|
2013
Q2 | $2.57M | Buy |
+96,655
| New | +$2.67M | 0.14% | 99 |
|
Other funds holding PFE
Ashfield Capital Partners's PFE Position: Q3 2022 in Review
Ashfield Capital Partners held its Pfizer (PFE) position steady in Q3 2022 at 99,496 shares worth $4.35M. The position accounts for 0.37% of the portfolio, ranked #66.
Ashfield Capital Partners first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $5.89M in Q4 2021. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- Ashfield Capital Partners held 99,496 shares of Pfizer worth $4.35M as of Q3 2022.
- Ashfield Capital Partners left its Pfizer share count unchanged in Q3 2022.
- Pfizer made up 0.37% of Ashfield Capital Partners's portfolio in Q3 2022, its #66 holding.
- Ashfield Capital Partners first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- Ashfield Capital Partners's Pfizer position peaked at $5.89M in Q4 2021.
- 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.